Business context and reporting period
The supplied filing is Owens & Minor, Inc.’s unaudited Form 10-Q for the three months ended March 31, 2016—not a filing identified as Accendra Health Inc. Owens & Minor describes itself as a global healthcare services company providing medical-product distribution, logistics and value-added services, plus clinical and procedural solutions. It reorganized reporting into Domestic, International and Clinical & Procedural Solutions (CPS), and recast prior-year segment results.
Financial performance and position
Amounts below are in U.S. dollars; financial statement figures are reported in thousands unless stated otherwise.
| Metric | Q1 2016 | Q1 2015 / comparison |
|---|---|---|
| Net revenue | $2.456 billion | $2.391 billion; up 2.7% |
| Gross margin | $296.6 million; 12.08% of revenue | $297.6 million; 12.45% |
| Operating earnings, GAAP | $45.0 million | $41.0 million |
| Net income | $24.1 million; diluted EPS $0.39 | $18.9 million; diluted EPS $0.30 |
| Adjusted operating earnings and EPS (non-GAAP) | $55.5 million; $0.50 | $50.9 million; $0.44 |
| Operating cash flow | $44.9 million | $168.7 million |
| Cash and cash equivalents | $190.3 million at March 31 | $161.0 million at December 31, 2015 |
| Long-term debt | $567.7 million at March 31 | $568.5 million at December 31, 2015 |
Gross margin dollars fell 0.3% year over year despite revenue growth. The filing attributes margin pressure in part to the U.K. customer contract exit and $2.1 million of unfavorable currency translation, partly offset by Domestic growth and manufacturer price-change income. DS&A declined 2.8% to $242.7 million, or 9.88% of revenue, from 10.44%. Interest expense was $6.8 million; the effective tax rate decreased to 36.8% from 44.4%.
Operating cash flow decreased substantially year over year, which management attributed primarily to routine working-capital timing, including vendor-payment timing in the prior-year period. Investing activities used $2.5 million, including $7.1 million of capital expenditures partly offset by $4.6 million of property-sale proceeds. Financing activities used $16.1 million, including $16.0 million in dividends and $5.6 million in share repurchases. Cash increased $29.3 million during the quarter.
At March 31, current assets were $2.001 billion and current liabilities were $1.067 billion. The $450 million revolving credit facility had no borrowings, approximately $5 million in letters of credit, and $445 million available. Senior notes comprise $275 million due 2021 at 3.875% and $275 million due 2024 at 4.375%; the filing states the company was in compliance with debt covenants.
Material changes versus the prior comparable period
- Domestic revenue rose 3.2% to $2.322 billion, with segment operating earnings increasing to $41.7 million from $38.1 million. Management cited larger healthcare-provider account growth, an additional sales day, cost controls and higher manufacturer price-change income.
- International revenue declined 12.5% to $83.6 million, reflecting $3.3 million of unfavorable currency translation and the mid-2015 exit of a U.K. customer contract. Segment operating results improved to income of $1.1 million from a loss of $0.3 million, with cost control and operating efficiency cited.
- CPS revenue increased 9.0% to $141.4 million, primarily from custom procedure tray sales; operating earnings edged up to $13.3 million from $13.2 million.
- Q1 2016 included $10.5 million of acquisition-related and exit/realignment charges, versus $9.9 million in Q1 2015. Exit and realignment charges included $9.9 million associated with a voluntary employee separation program and other severance activities. Adjusted results exclude these charges and are non-GAAP measures.
- The effective tax rate fell, which management attributed to a higher share of pretax income earned in lower-tax jurisdictions and deductibility of certain prior-year acquisition charges.
Outlook, risks and unusual items
The filing provides no specific revenue, earnings or cash-flow guidance. Management said it expects available cash generation and borrowing capacity to meet working-capital, capital expenditure, growth, debt-service, dividend and repurchase needs. It anticipates continuing quarterly dividends, subject to Board discretion and business conditions.
Risks identified include pricing and competitive pressure; customer or supplier concentration and changes in purchasing; healthcare regulation; successful execution of strategic initiatives and acquisitions; foreign currency and international-market exposure; fuel costs; financing access and interest rates; information-system interruption or data-security breaches; and litigation, product-liability and tax contingencies. Management reported no material developments in previously disclosed legal proceedings and no material changes to the prior-year risk factors. It also reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
Other notable items: the company repurchased approximately 163,000 shares for $5.6 million, with $64.4 million remaining under a program expiring in February 2017. It reported no goodwill impairment in its interim analysis following segment realignment. New lease-accounting and share-based-payment standards were under evaluation; adoption of the debt-issuance-cost presentation standard did not affect earnings or cash flows.
Investor verification points
- Confirm the issuer identity: the supplied filing names Owens & Minor, Inc., despite the request metadata naming Accendra Health Inc.
- Assess the sustainability of earnings improvement, including the effect of excluded acquisition and realignment charges and the company’s non-GAAP adjustments.
- Review the sharp year-over-year decline in operating cash flow and working-capital movements, particularly receivables, payables and vendor-payment timing.
- Monitor Domestic margin trends and International recovery, including the impact of the lost U.K. contract and foreign-currency changes.
- Verify debt-covenant headroom, revolving-credit availability, and the discretionary nature of future dividends and share repurchases.